HC Wainwright Reaffirms "Buy" Rating for Alto Neuroscience (NYSE:ANRO)

Key Points

• HC Wainwright has reiterated a buy rating for Alto Neuroscience (ANRO) with a target price of $10.00, indicating a potential upside of 203.49% from its previous close.
• Shares of Alto Neuroscience recently traded up 4.9% to $3.30, with a market capitalization of $89.23 million and a current ratio of 18.43.
• The company, involved in clinical-stage biopharmaceuticals, missed earnings estimates with a reported EPS of ($0.65) for the last quarter.

Alto Neuroscience (NYSE:ANRO - Get Free Report)'s stock had its "buy" rating reaffirmed by HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $10.00 price target on the stock. HC Wainwright's price objective would indicate a potential upside of 155.95% from the company's current price. HC Wainwright also issued estimates for Alto Neuroscience's Q3 2025 earnings at ($0.74) EPS, Q4 2025 earnings at ($0.76) EPS, FY2025 earnings at ($2.69) EPS, Q1 2026 earnings at ($0.85) EPS, Q2 2026 earnings at ($0.87) EPS, Q3 2026 earnings at ($0.89) EPS, Q4 2026 earnings at ($0.69) EPS, FY2026 earnings at ($3.26) EPS, FY2027 earnings at ($3.23) EPS, FY2028 earnings at ($3.13) EPS and FY2029 earnings at ($1.77) EPS.

Separately, Wedbush reaffirmed a "neutral" rating and issued a $4.00 price objective on shares of Alto Neuroscience in a research note on Thursday, May 15th. Four research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, Alto Neuroscience currently has a consensus rating of "Moderate Buy" and an average target price of $8.50.

Alto Neuroscience Trading Up 8.8%

NYSE:ANRO traded up $0.3170 during trading hours on Monday, hitting $3.9070. 157,542 shares of the company were exchanged, compared to its average volume of 102,544. The stock has a market capitalization of $105.80 million, a price-to-earnings ratio of -1.63 and a beta of 1.84. The company has a current ratio of 18.43, a quick ratio of 18.43 and a debt-to-equity ratio of 0.18. Alto Neuroscience has a one year low of $1.60 and a one year high of $15.04. The company has a fifty day simple moving average of $2.80 and a 200 day simple moving average of $2.72.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last announced its earnings results on Wednesday, August 13th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Sell-side analysts expect that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

Hedge Funds Weigh In On Alto Neuroscience

Several institutional investors have recently modified their holdings of the company. Wells Fargo & Company MN boosted its holdings in shares of Alto Neuroscience by 40.0% during the fourth quarter. Wells Fargo & Company MN now owns 10,989 shares of the company's stock worth $46,000 after purchasing an additional 3,139 shares during the period. Deutsche Bank AG grew its position in Alto Neuroscience by 31.3% during the 4th quarter. Deutsche Bank AG now owns 15,210 shares of the company's stock valued at $64,000 after purchasing an additional 3,629 shares during the last quarter. Jane Street Group LLC grew its position in Alto Neuroscience by 72.0% during the 4th quarter. Jane Street Group LLC now owns 18,600 shares of the company's stock valued at $79,000 after purchasing an additional 7,783 shares during the last quarter. AlphaCore Capital LLC grew its position in Alto Neuroscience by 100.0% during the 2nd quarter. AlphaCore Capital LLC now owns 20,000 shares of the company's stock valued at $44,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Barclays PLC raised its position in Alto Neuroscience by 34.5% in the 4th quarter. Barclays PLC now owns 39,807 shares of the company's stock worth $168,000 after buying an additional 10,208 shares during the last quarter.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.